Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +52.24%
#3 Glidr Glidr +36.41%
#4 Walrus Walrus +29.81%
#5 Cysic Cysic +20.00%
#6 The Black Bull The Black Bull +18.44%
#7 Humanity Humanity +15.87%
#8 Fabric Protocol Fabric Protocol +14.98%
#9 Nockchain Nockchain +14.31%
#10 Tutorial Tutorial +13.13%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Restart Life Sciences Corp. Restart Life Sciences Corp.

Restart Life Sciences Corp.

HEAL
Rank in Stocks #37250
Operating internationally through its various subsidiaries, Restart Life... Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.
Share Price
$0.05137558
Last synced: 2026-08-13
Market Cap
$1.88M
Change (1 day)
0.00%
Change (1 year)
-11.66%
Country
CA
Trade Restart Life Sciences Corp. (HEAL)

Category

Healthcare
Revenue for Restart Life Sciences Corp. (HEAL)
Revenue in Aug 2026 TTM: 0
According to Restart Life Sciences Corp. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Restart Life Sciences Corp. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE